Targeted Delivery of Panitumumab-Scaffold Bosutinib-Encapsulated Polycaprolactone Nanoparticles for EGFR-Overexpressed Colorectal Cancer
Sankha Bhattacharya, Vipan K. Parihar, Neeraj Singh, Ketan Hatware, Amit Page, Mayank Sharma, Mahendra Prajapati, Abhishek Kanugo, Datta Maroti Pawde, Saurabh Maru, Girdhari Lal Gupta, Sunil Kanvinde
Abstract
Aims: Panitumumab (anti-Erb)-conjugated polycaprolactone (PCL) nanoparticles loaded with bosutinib (BTNB) were used to develop a targeted drug-delivery system for colon cancer cells. Materials & methods: Using carbodiimide coupling, anti-Erb was conjugated to BTNB-loaded PCL nanoparticles. Dynamic light scattering, scanning electron microscopy, transmission electron microscopy, Fourier-transform infrared spectroscopy, differential scanning calorimetry, x-ray diffraction and thermogravimetric analysis were used to analyze nanoparticles. Results: According to in vitro studies, anti-Erb-BTNB-PCL nanoparticles inhibited HCT116 cells more than BTNB alone. Cell arrest at different phases was examined for apoptotic potential. An in vivo efficacy study showed that anti-Erb-BTNB-PCL nanoparticles could target tumors selectively. Conclusion: Anti-Erb-conjugated BTNB nanoparticles could specifically target colon cancer.